1.Findling, RL.Atypical antipsychotics in the treatment of children and adolescents.
J Clin Psychiatry 2004;65(Suppl. 6):3–29.
Laje, G.National trends in the outpatient treatment of children and adolescents with antipsychotic drugs.
Arch Gen Psychiatry 2006;63:679–685.
McCracken, JT.Second-generation antipsychotic medications in children and adolescents.
J Child Adolesc Psychopharmacol 2004;14:372–394.
Soh, Net al. Side effects of second generation antipsychotics: the experience, views and monitoring practices of Australian child psychiatrists.
Aust Psychiatry 2008;16:253–262.
Handy, S.Survey of atypical antipsychotic medication used by children and adolescent psychiatrists.
Child Adolesc Ment Health 2006;11:164–167.
Steele, M.Survey of atypical antipsychotic prescribing by Canadian child psychiatrists and developmental pediatricians for patient age under 18 years.
Can J Psychiatry 2007;52:363–368.
Sewell, JRet al. Prescribing of psychotropic medications for children by Australian pediatricians and child psychiatrists.
De Smedt, G,
Van Dongen, S.Risperidone in children with disruptive behavior disorders and subaverage intelligence: a 1-year, open-label study of 504 patients.
J Am Acad Child Adolesc Psychiatry 2005;44:64–72.
Eerdekens, M.Long-term use of risperidone in children with disruptive behavior disorders and subaverage intelligence: efficacy, safety and tolerability.
J Child Adolesc Psychopharmacol 2006;16:260–272.
Eerdekens, M.Long-term safety and efficacy of risperidone in children with disruptive behaviour disorders: results of a 2-year extension study.
Eur Child Adolesc Psychiatry 2005;15:97–104.
11.Correll, CU.Metabolic side effects of second-generation antipsychotics in children and adolescents: a different story.
J Clin Psychiatry 2005;66:1331–1332.
12.Correll, CU.Endocrine and metabolic adverse effects of psychotropic medications in children and adolescents. J Am Acad Child Adolesc Psychiatry 2006;45:771–791.
13.Correll, CU.Antipsychotic use in children and adolescents: minimizing adverse effects to maximise outcomes. J Am Acad Child Adolesc Psychiatry 2008;47:9–20.
Voruganti, LN.Intervention research in psychosis: issues related to the assessment of quality of life.
Schizophr Bull 2000;26:557–564.
McDougle, CJet al. Acute and long-term safety and tolerability of risperidone in children with autism.
J Child Adolesc Psychopharmacol 2005;15:869–884.
Bentall, RP.A Self-Rating Scale for Measuring Neuroleptic Side-Effects – validation in a group of schizophrenic patients.
Br J Psychiatry 1995;166:650–653.
17.Lambert, TJR.Measurement of antipsychotic-induced side-effects: support for the validity of a self-report (LUNSERS) versus structured interview (UKU) approach to measurement.
Hum Psychopharmacol 2003;18:405–411.
Elgen, K.The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic treated patients. Acta Psychiatr Scand 1987;76:1–100.
Seeman, MV.Quality of life measurement in schizophrenia: reconciling the quest for subjectivity with the question of reliability.
Psychol Med 1998;28:165–172.
Gorman, JM.Assessment of insight in psychosis.
Am J Psychiatry 1993;150:873–879.
Hunt, Get al. Duration of treatment and self-reported neuroleptic side-effects of low dose risperidone in children and adolescents.
Aust Psychiatry 2010;18:42–45.
Collings, P.The use of the Liverpool University Side Effect Rating Scale (LUNSERS) in clinical practice.
Aust N Z J Ment Health Nurs 2000;9:166–176.